UUDA Stock Overview
Operates as a clinical-stage drug development company that focuses on blood-related cancers in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Syntara Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.021 |
| 52 Week High | AU$0.028 |
| 52 Week Low | AU$0.008 |
| Beta | 0.61 |
| 11 Month Change | -10.64% |
| 3 Month Change | 27.27% |
| 1 Year Change | 50.00% |
| 33 Year Change | -63.16% |
| 5 Year Change | -86.27% |
| Change since IPO | -97.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| UUDA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -2.3% | 1.4% | 0.8% |
| 1Y | 50.0% | -18.4% | 9.1% |
Return vs Industry: UUDA exceeded the German Pharmaceuticals industry which returned -18.4% over the past year.
Return vs Market: UUDA exceeded the German Market which returned 9.1% over the past year.
Price Volatility
| UUDA volatility | |
|---|---|
| UUDA Average Weekly Movement | 24.4% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: UUDA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: UUDA's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 21 | Gary Phillips | syntaratx.com.au |
Syntara Limited operates as a clinical-stage drug development company that focuses on blood-related cancers in Australia. The company’s lead product candidate is SNT-5505, which is in Phase 2 trial to treat myelofibrosis, myelodysplastic syndrome, hepatocellular carcinoma, and pancreatic cancer, as well as scar prevention. It also develops SNT-4728 in Phase 2 trial for the treatment of neurodegenerative diseases comprising isolated rapid eye movement sleep behavior disorder (IRBD) and Parkinson’s disease; SNT-5382, which is a selective lysyl oxidase-like 2 inhibitor in Phase 1 trial to treat chronic fibrosis; and SNT-8370 for the treatment of inflammation.
Syntara Limited Fundamentals Summary
| UUDA fundamental statistics | |
|---|---|
| Market cap | €35.57m |
| Earnings (TTM) | -€8.43m |
| Revenue (TTM) | €3.56m |
10.0x
P/S Ratio-4.2x
P/E RatioIs UUDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UUDA income statement (TTM) | |
|---|---|
| Revenue | AU$5.76m |
| Cost of Revenue | AU$8.30m |
| Gross Profit | -AU$2.53m |
| Other Expenses | AU$11.13m |
| Earnings | -AU$13.67m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.01 |
| Gross Margin | -43.98% |
| Net Profit Margin | -237.09% |
| Debt/Equity Ratio | 0.2% |
How did UUDA perform over the long term?
See historical performance and comparison